UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 29, 2019
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware
13-5315170
(State of Incorporation)
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.05 par value
PFE
New York Stock Exchange
0.000% Notes due 2020
PFE20A
New York Stock Exchange
0.250% Notes due 2022
PFE22
New York Stock Exchange
1.000% Notes due 2027
PFE27
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
At November 4, 2019, 5,534,122,364 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three and nine months ended September 29, 2019 and
September 30, 2018
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 29, 2019
and September 30, 2018
Condensed Consolidated Balance Sheets as of September 29, 2019 and December 31, 2018
Condensed Consolidated Statements of Equity for the three and nine months ended September 29, 2019 and
September 30, 2018
Condensed Consolidated Statements of Cash Flows for the nine months ended September 29, 2019 and
September 30, 2018
10
Notes to Condensed Consolidated Financial Statements
12
Review Report of Independent Registered Public Accounting Firm
52
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
53
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
114
Item 4.
Controls and Procedures
114
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
115
Item 1A.
Risk Factors
115
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
116
Item 3.
Defaults Upon Senior Securities
116
Item 4.
Mine Safety Disclosures
116
Item 5.
Other Information
116
Item 6.
Exhibits
117
Signature
118
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2018 Financial Report
Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018
2018 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2018
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
Akcea
Akcea Therapeutics, Inc.
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Allogene
Allogene Therapeutics, Inc.
Anacor
Anacor Pharmaceuticals, Inc.
AOCI
Accumulated Other Comprehensive Income
Array
Array BioPharma Inc.
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
Bain Capital
Bain Capital Private Equity and Bain Capital Life Sciences
Bamboo
Bamboo Therapeutics, Inc.
Biopharma
Pfizer Biopharmaceuticals Group
BMS
Bristol-Myers Squibb Company
CAR T
chimeric antigen receptor T cell
CDC
U.S. Centers for Disease Control and Prevention
Cerevel
Cerevel Therapeutics, LLC
cGMP
current Good Manufacturing Practices
Citibank
Citibank, N.A.
Developed Markets
U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and
New Zealand
EGFR
epidermal growth factor receptor
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea),
Latin America, Eastern Europe, the Middle East, Africa, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development organization
GSK
GlaxoSmithKline plc
GS&Co.
Goldman, Sachs & Co. LLC
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
Ionis
Ionis Pharmaceuticals, Inc.
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson
JV
Joint Venture
King
King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCC
Merkel cell carcinoma
MCO
managed care organization
mCRC
metastatic colorectal cancer
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation LLC (formerly Medivation, Inc.)
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
Mylan
Mylan N.V.
NDA
new drug application
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
pharmacy benefit manager
Pharmacia
Pharmacia Corporation
PP&E
property, plant & equipment
PsA
psoriatic arthritis
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2019
RA
rheumatoid arthritis
RCC
renal cell carcinoma
R&D
research and development
ROU
right of use
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SFJ
SFJ Pharmaceuticals Group
Shire
Shire International GmbH
SI&A
selling, informational and administrative
S&P
Standard and Poor s
TCJA
legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017
Therachon
Therachon Holding AG
UC
ulcerative colitis
U.K.
United Kingdom
U.S.
United States
ViiV
ViiV Healthcare Limited
VBP
Volume-based procurement program
WRDM
Worldwide Research, Development and Medical
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
September 29,
2019
September 30,
2018
September 29,
2019
September 30,
2018
Revenues
12,680
13,298
39,062
39,670
Costs and expenses:
Cost of sales(a)
2,602
2,694
7,611
8,173
Selling, informational and administrative expenses(a)
3,260
3,494
10,110
10,448
Research and development expenses(a)
2,283
2,008
5,827
5,549
Amortization of intangible assets
1,212
1,253
3,578
3,640
Restructuring charges and certain acquisition-related costs
365
85
295
172
(Gain) on completion of Consumer Healthcare JV transaction
(8,087
(8,087
Other (income)/deductions net
319
(414
537
(1,143
Income from continuing operations before provision for taxes on income
10,727
4,177
19,190
12,831
Provision for taxes on income
3,047
66
2,566
1,270
Income from continuing operations
7,680
4,111
16,625
11,562
Discontinued operations net of tax
11
10
Net income before allocation to noncontrolling interests
7,684
4,122
16,628
11,571
Less: Net income attributable to noncontrolling interests
19
25
Net income attributable to Pfizer Inc.
7,680
4,114
16,609
11,546
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
1.38
0.70
2.98
1.96
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
1.38
0.70
2.98
1.96
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
1.36
0.69
2.92
1.92
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
1.36
0.69
2.92
1.92
Weighted-average shares basic
5,545
5,875
5,581
5,899
Weighted-average shares diluted
5,649
5,986
5,690
5,998
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
Nine Months Ended
(MILLIONS OF DOLLARS)
September 29,
2019
September 30,
2018
September 29,
2019
September 30,
2018
Net income before allocation to noncontrolling interests
7,684
4,122
16,628
11,571
Foreign currency translation adjustments, net
(468
(567
(628
(507
Reclassification adjustments(a)
268
(2
270
(22
(200
(569
(358
(530
Unrealized holding gains on derivative financial instruments, net
150
222
241
236
Reclassification adjustments for (gains)/losses included in net income(b)
(29
(235
(372
119
122
(13
(131
355
Unrealized holding gains/(losses) on available-for-sale securities, net
15
149
48
(65
Reclassification adjustments for (gains)/losses included in net income(b)
(7
(36
30
(67
Reclassification adjustments for unrealized gains included in Retained earnings(c)
(462
112
77
(595
Benefit plans: actuarial gains/(losses), net
(171
(175
114
Reclassification adjustments related to amortization
60
60
180
183
Reclassification adjustments related to settlements, net
38
42
40
108
Other
42
49
60
69
(31
158
105
474
Benefit plans: prior service costs and other, net
(1
Reclassification adjustments related to amortization of prior service costs and other, net
(44
(46
(137
(137
Reclassification adjustments related to curtailments of prior service costs and other, net
(46
(4
(46
(18
Other
(88
(50
(180
(154
Other comprehensive loss, before tax
(190
(361
(486
(449
Tax provision on other comprehensive loss
84
62
50
667
Other comprehensive loss before allocation to noncontrolling interests
(275
(422
(536
(1,116
Comprehensive income before allocation to noncontrolling interests
7,409
3,700
16,092
10,455
Less: Comprehensive income/(loss) attributable to noncontrolling interests
(6
Comprehensive income attributable to Pfizer Inc.
7,415
3,700
16,084
10,450
(a)
For the third quarter and first nine months of 2019, the foreign currency translation adjustments are primarily reclassified into (Gain) on completion of Consumer Healthcare JV transaction in the condensed consolidated statements of income as a result of the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK. See Note 2B. The remaining foreign currency translation adjustments are reclassified into Other (income)/deductions net in the condensed consolidated statements of income.
(b)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Other (income)/deductions net and Cost of sales, see Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(c)
For additional information, see Notes to Consolidated Financial Statements Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 in our 2018 Financial Report.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
September 29,
2019
December 31,
2018
(Unaudited)
Assets
Cash and cash equivalents
2,785
1,139
Short-term investments
6,302
17,694
Trade accounts receivable, less allowance for doubtful accounts: 2019 $541; 2018 $541
9,439
8,025
Inventories
8,222
7,508
Current tax assets
3,730
3,374
Other current assets
2,954
2,461
Assets held for sale
29
9,725
Total current assets
33,459
49,926
Equity-method investments
15,999
181
Long-term investments
2,723
2,586
Property, plant and equipment, less accumulated depreciation: 2019 $16,728; 2018 $16,591
13,701
13,385
Identifiable intangible assets, less accumulated amortization
38,995
35,211
Goodwill
58,665
53,411
Noncurrent deferred tax assets and other noncurrent tax assets
1,984
1,924
Other noncurrent assets
4,920
2,799
Total assets
170,446
159,422
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2019 $2,431; 2018 $4,776